Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Pharmacognosy ResearchNOW IN
    Article

    Hepatoprotective Assessment of Copper Calx against Anti-Tubercular Drug-induced Hepatotoxicity in Rats

    Mohammad Sharique1, Hariprasad M.G1,2★, Moqbel Ali Moqbel Redhwan1,2, Ashish Jain1, Shambhavi S1, Mamatha A3, Niranjana Niranjana4★ Corresponding author

    1. 1Department of Pharmacology, KLE College of Pharmacy, Bengaluru, Karnataka, INDIA.
    2. 2Basic Science Research Center (Off-Campus), KLE College of Pharmacy, Bengaluru, Karnataka, INDIA.
    3. 3Department of Pharmacognosy, KLE College of Pharmacy, Bengaluru, Karnataka, INDIA.
    4. 4Pentacare Ayur Pharma, Malleshwaram, Bengaluru, Karnataka, INDIA.

    CORRESPONDENCE

    Hariprasad M.G

    Department of Pharmacology, KLE College of Pharmacy, Bengaluru, Karnataka, INDIA.

    hariprasadmg@klepharmblr.org

    Received: 26-04-2023; Revised: 27-06-2023; Accepted: 21-08-2023.

    Volume 15, Issue 4 · pp. 806–812 · PUBLISHED · DOI: 10.5530/pres.15.4.085

    View on Pharmacogn. Res. original site ↗

    ABSTRACT

    Background:Anti-Tubercular Drugs (ATDs), while effective in treating tuberculosis, are associated with hepatotoxicity, leading to liver damage and complications. Calx of Copper, a traditional Ayurvedic preparation, has shown potential hepatoprotective properties. Objectives:To investigate the potential hepatoprotective role of Calx of Copper in mitigating ATD-induced hepatotoxicity and to examine its impact on liver function markers and histopathological changes in rats. Materials and Methods: Thirty male Wistar rats were randomly divided into five groups (n=6 per group): control, ATD, Calx of Copper, ATD+Calx of Copper, and silymarin (used as a standard hepatoprotective agent). Hepatotoxicity was induced in the ATD, ATD+Calx of Copper, and silymarin groups by administering a combination of isoniazid, rifampicin, and pyrazinamide for 25 days. Calx of Copper and silymarin were orally administered at doses of 6.17 mg/kg and 12.33 mg/kg, and 300 mg/kg b.w, respectively, in their respective groups. Liver function markers, including serum transaminase and alanine Aminotransferase (ALT), were measured at the end of the study. A histopathological examination of liver tissues was also performed. Results: ATDinduced hepatotoxicity was evident through elevated serum SGPT, SGOT, ALT, and ALP levels and histopathological alterations in liver tissue. Co-administration of Calx of Copper significantly reduced SGPT, SGOT, ALT, and ALP (p<0.05) and improved liver histopathological changes compared to the ATD group. The hepatoprotective effect of Calx of Copper was comparable to that of silymarin. Conclusion:Copper calx demonstrated significant hepatoprotective activity against ATD-induced hepatotoxicity in rats, as evidenced by normalizing liver function markers and histopathological improvements. These findings suggest that Calx of Copper may be a promising adjuvant therapy for mitigating liver damage associated with anti-tubercular drug treatment.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Sharique, M., M.G, H., Redhwan, M. A. M., Jain, A., S, S., A, M., & Niranjana, N. (). Hepatoprotective Assessment of Copper Calx against Anti-Tubercular Drug-induced Hepatotoxicity in Rats. Pharmacognosy Research, 15(4), 806–812. https://doi.org/10.5530/pres.15.4.085